Sign up
Pharma Capital

Alliance Pharma to bank £2.9mln from the sale of Chinese rights to pregnancy supplement

A £1.5mln shareholder loan will also be repaid, the company told investors
Pregnant woman
Forceval a micro-nutrient supplement used in pregnancy

Alliance Pharma plc (LON:APH) is selling the Chinese rights to Forceval, a micro-nutrient supplement used in pregnancy, for £2.9mln.

It doing so via the disposal of its 60% stake in a company called Unigreg Limited to Pacific Glory Development.

As well as the sale proceeds, which will be staggered over two payments, with the final £500,000 instalment expected within the next year, Alliance will be repaid a £1.5mln shareholder loan.

Bank debt reduced

The proceeds of the deal will be used to reduce bank debt.

Alliance said it remains committed to China, having set up an affiliate in Shanghai to sell a range child nutraceutical products in the People’s Republic. It also has a distributor in the same city for its Kelo-cote product for scarring.

Alliance also confirmed it will continue to market the Forceval brand in the UK.

Ian_55ae0ddd437b7.jpg
Why Invest In Alliance Pharma plc? Read More Here

Register here to be notified of future APH Company articles
View full APH profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.